NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Therapeutic effects of a novel compound on Friend retrovirus disease in mouse.

Tournaire R, Arnaud S, Hamedi-Sangari F, Thomasset N, Dore JF, Vila J; International Conference on AIDS.

Int Conf AIDS. 1991 Jun 16-21; 7: 103 (abstract no. W.A.1047).

INSERM U.218, Centre Leon Berard, France

OBJECTIVE: To determine in vivo efficacy of D-ASPARTIC beta-HYDROXAMATE (DAH) against Friend Virus polycythemic strain (FVP) and to specify the biological effects of this analogue. METHODS AND RESULTS: DAH shows, when administered daily at different doses (1 to 3 g/Kg/dose) in ip injection beginning at 1-3 and 18 days post-inoculation (pi) of FVP in DBA/2 mice a marked prolongation of mean survival time. Infected mice at 3 days pi were treated with 2 g/Kg/dose of DAH (1 dose/day-8 days) and killed 16 days later. The percentage of inhibition of splenomegaly was 94%. With the same dose of DAH, a treatment beginning 18 days pi during 9 days shows a drastic regression of splenomegaly: mean spleen weight measured on day 27 pi for treated mice was 0.64 g as compared to 3.05 g for untreated mice and to 1.93 g for untreated mice on day 18 pi. The effects of DAH treatment (started 3 days pi-2 g/kg/dose x 1 dose/day-95 days) on survival of FVP infected mice and on FVP target cells: CFU-E (erythropoietic colony forming units), was analysed. Control animals had a median survival of 29 days as compared to 100 days for those treated with DAH. A transitory anemia was observed. DAH suppresses (89%-19 days pi) splenic FVP-leukemic CFU-E. Furthermore, we tested in vitro toxicity of DAH on spleen CFU-E. The preincubation for one hour with 3 mM of DAH, inhibited infected CFU-E colony formation by 23% and had no effect on uninfected CFU-E (control mice + ip phenylhydrazine) (p less than 0.02). CONCLUSION: DAH has therapeutic activity of FVP in vitro and in vivo in mice. These results suggest potential therapeutic effect in human retroviral disease.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Anemia
  • Animals
  • Erythroid Progenitor Cells
  • Erythropoiesis
  • Friend murine leukemia virus
  • Humans
  • In Vitro
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Mice, Inbred DBA
  • Mice, Inbred Strains
  • Retroviridae Infections
  • Spleen
  • Splenomegaly
Other ID:
  • 3104791
UI: 102192239

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov